Duke Cancer Institute ( Site 3005)

Durham, North Carolina 27710

0 studies enrolling now · 1 studies all time

What they study most

Melanoma

Studies at this site

• Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) — Completed